Multiple immune cell populations and receptors

The term Multiple immune cell populations and receptors refers to a broad and heterogeneous group of biological entities rather than a single, specific therapeutic target. It encompasses various leukocyte subsets, such as T cells, B cells, myeloid cells, and natural killer cells, along with the diverse array of surface receptors—including T-cell receptors (TCRs), B-cell receptors (BCRs), and checkpoint proteins—that govern their activity (Abbas et al., 2018). In drug development, this classification is often used to describe the systemic effects of immunotherapies or the complex cellular environment of the tumor microenvironment (Pardoll, 2012). Because it does not define a specific molecular structure or pathway, it cannot be targeted by a single pharmacological agent in a conventional sense. Instead, therapeutic strategies typically focus on specific components within this group to modulate the overall immune response in diseases like cancer, autoimmunity, and chronic inflammation (Janeway et al., 2001). Consequently, while these populations are the site of action for many blockbuster drugs, the phrase itself serves as a categorical descriptor rather than a precise molecular target.

Other names

Immune cell subsetsLeukocyte populationsImmune receptorsImmune system componentsHematopoietic cell populations

Drugs interacting with these populations typically function through the agonism or antagonism of specific surface receptors (e.g., checkpoint inhibition), the depletion of specific cell subsets (e.g., B-cell depletion via CD20 targeting), or the modulation of cytokine signaling pathways to alter immune activation states.